• Greenwich Lifesciences’ board extended the share lock-up for directors, officers, and certain pre-IPO investors to Jan. 31, 2027.
• The restriction keeps a 100% lock-up in place, barring sales unless the board modifies the terms.
• Post-lock-up sales would shift to a leak-out plan with daily and period limits, unless the board changes the framework.
• The board retained flexibility to end all or part of the lock-up early or adopt a leak-out plan or 10b5-1 selling program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100600PRIMZONEFULLFEED9806461) on August 10, 2026, and is solely responsible for the information contained therein.